Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05075122
Title Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab (FOCUS)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Martin-Luther-Universität Halle-Wittenberg

head and neck squamous cell carcinoma


Pembrolizumab + Sargramostim + UV1 Telomerase peptide vaccine


Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.